MDRNA (NASDAQ: [[ticker:MRNA]]), the Bothell, WA-based developer of RNA interference drugs, said today it has reduced its board from eight members to five as part of its cash conservation efforts. Former CEO Steven Quay, Alex Cross, and Jack Pollack are off the new board, while Bruce Thaw, Dan Peters, James Rothman, Greg Sessler, and CEO J. Michael French will remain on the board, after yesterday’s annual shareholder meeting.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
